|Day Low/High||50.83 / 52.49|
|52 Wk Low/High||31.97 / 64.48|
It is two totally different markets when you compare the small-cap action to the big-cap indices.
We are seeing a focus on finding smaller names that may offer interesting valuations and stories.
This underperformance is being caused by pockets of weakness in bigger-cap names.
The key for the overall market now is that it hold above today's early lows.
There is no question that we are becoming extended and ripe for some profit taking.
Sector charts should shape up as worries about prices are finally put to rest.
Overall it is still a positive day but the action is sloppy.
Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.
The challenge of this market is that the upward moves have not been well sustained.
Jim Cramer focuses on Walgreens Boots Alliance, Arena Pharmaceutical, Dominion Energy, Tower Semiconductor, Idexx, LexinFintech Holdings and more.
It's not all about the bond market, says Jim Cramer. The central issues here are trade, tariffs and most important, the stocks themselves, like Facebook and Amazon.
Investors in Arena Pharmaceuticals Inc saw new options become available today, for the June 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new June 8th contracts and identified one put and one call contract of particular interest.
Rotational action is the main theme Wednesday and good opportunities are out there.
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the May 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new May 11th contracts and identified one put and one call contract of particular interest.
There's a worrisome scenario that could develop this afternoon.
In recent trading, shares of Arena Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $36.00, changing hands for $36.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.
Jim Cramer says it's a very rare moment when the absence of negatives, however fleeting or relative, creates a stampede of buying.
Jim Cramer is bullish on Allergan, USG Corp, and Arena Pharmaceuticals.
Former hedge funder and biotech CEO Martin Shkreli finds himself in limbo as a criminal jury now decides if allegations of fraud will put him in orange coveralls.
The company just beat a bench mark, previously set by Johnson & Johnson.
Jim Cramer is bullish on Xilinx, Arena Pharmaceuticals, Magellan Midstream, Altria and Bank of Montreal.
Cramer says it's the sign of a good market: Investors are finding value in the stocks that were left behind.
Big gains could be ahead for investors willing to stick with the stock, according to one firm.
Alexion, Arena and Novavax were among the biotech stock movers ahead of the market open on Friday, July 7.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.